CJC-1295
Synthetic tetrasubstituted growth hormone-releasing hormone (GHRH) 1-29 analogue. Exists in two distinct formulations: CJC-1295 with DAC (Drug Affinity Complex, covalent albumin binder with ~6-8 day half-life) and CJC-1295 without DAC (Mod GRF 1-29, ~30 min half-life). Clinical development by ConjuChem was terminated following a fatal cardiovascular event in a Phase 2 trial. Unapproved by FDA.
60-Second Scientific Briefing
CJC-1295 is an investigational synthetic 29-amino acid GHRH analogue engineered with tetrasubstitutions to resist enzymatic degradation by DPP-IV. CJC-1295 with DAC incorporates a maleimidopropionyl group that conjugates to endogenous serum albumin, extending its half-life to several days. It is NOT FDA-approved and clinical trials were terminated.
What is CJC-1295?
Pharmacological Classification & Molecular IdentitySynthetic 29-amino-acid modified growth hormone-releasing hormone analogue modified to resist dipeptidyl peptidase IV cleavage.
Verified Chemical & Regulatory Registry Identifiers
Mechanism of Action & Receptor Targets
Biological Pathway and Target BindingBiological pathway and target receptor binding mechanism.
Receptor Selectivity: Activates pituitary GHRH receptors, stimulating sustained growth hormone synthesis and chronic elevation of circulating IGF-1 concentrations.
Regulatory & FDA Approval Status
Legal and Regulatory ClassificationsNot approved by the US FDA for any indication. Placed on the FDA 503A Category 2 list due to safety concerns. Prohibited at all times by WADA under Category S2.
CJC-1295 is not approved for commercial sale, prescription therapy, or compounded medication distribution. It exists strictly within authorized scientific and clinical research frameworks.
Human Evidence & Clinical Trials
Clinical Study Readouts and Evidence SynthesesEvaluated in healthy adults (JCEM 2006) demonstrating prolonged GH/IGF-1 elevation. Clinical development was terminated during Phase 2 trials.
Clinical Evidence
Evaluated in healthy adults (JCEM 2006) demonstrating prolonged GH/IGF-1 elevation. Clinical development was terminated during Phase 2 trials.
Safety Profile & Clinical Limitations
Documented Adverse Events and Known UncertaintiesInjection site pain, headache, diarrhea, flushing, and water retention. Clinical trials were halted due to serious adverse safety events including a patient death in a clinical trial cohort.
Long-term continuous stimulation of somatotropes and sustained supra-physiological IGF-1 exposure.
Dose Approval Status
Commercial Dosing Status and Policy DirectivesNOT ESTABLISHED. No approved human dose exists.
Under Egypt Peptides medical governance policies, no personal dosages, titration intervals, cycles, stacking recommendations, or self-injection instructions may be provided for unapproved investigational compounds. Clinical study protocols represent controlled experimental research parameters exclusively.
What is Known vs. What is Unknown
Evidence Comparison and Clinical Evidence Boundaries✓ Confirmed Scientific Evidence
- Synthetic 29-amino-acid modified growth hormone-releasing hormone analogue modified to resist dipeptidyl peptidase IV cleavage.
- Targets & Selectivity: Activates pituitary GHRH receptors, stimulating sustained growth hormone synthesis and chronic elevation of circulating IGF-1 concentrations.
- Evaluated in healthy adults (JCEM 2006) demonstrating prolonged GH/IGF-1 elevation. Clinical development was terminated during Phase 2 trials.
- Safety considerations: Injection site pain, headache, diarrhea, flushing, and water retention. Clinical trials were halted due to serious adverse safety events including a patient death in a clinical trial cohort.
? Unknown / Under Ongoing Investigation
- Long-term continuous stimulation of somatotropes and sustained supra-physiological IGF-1 exposure.
Verified Questions & Answers
10 Verified scientific answers with permanent anchor keysCJC-1295 is classified as a Growth Hormone-Releasing Hormone (GHRH) Analogue. Molecular structure: Synthetic 29-amino-acid modified growth hormone-releasing hormone analogue modified to resist dipeptidyl peptidase IV cleavage..
Pharmacological classification and molecular integrity are documented in verified regulatory and scientific literature.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (The Journal of Clinical Endocrinology & Metabolism, 2006-03-01)
CJC-1295 exerts biological activity via Activates pituitary GHRH receptors, stimulating sustained growth hormone synthesis and chronic elevation of circulating IGF-1 concentrations..
Receptor binding affinity and selectivity dictate the physiological response observed in laboratory and clinical trials.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (The Journal of Clinical Endocrinology & Metabolism, 2006-03-01)
Regulatory status: Not approved by the US FDA for any indication. Placed on the FDA 503A Category 2 list due to safety concerns. Prohibited at all times by WADA under Category S2.
Investigational and research-only compounds cannot be legally distributed or marketed as prescription drugs.
- World Anti-Doping Agency (WADA) Prohibited List: Non-Approved Substances (S0) and Peptide Hormones (S2) (World Anti-Doping Agency, 2024-01-01)
- FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) (U.S. Food and Drug Administration, 2023-09-29)
Clinical evaluation status: Evaluated in healthy adults (JCEM 2006) demonstrating prolonged GH/IGF-1 elevation. Clinical development was terminated during Phase 2 trials.
Clinical trial readouts and systematic analyses establish the boundary between demonstrated findings and experimental hypotheses.
- FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) (U.S. Food and Drug Administration, 2023-09-29)
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (The Journal of Clinical Endocrinology & Metabolism, 2006-03-01)
Reported safety profile: Injection site pain, headache, diarrhea, flushing, and water retention. Clinical trials were halted due to serious adverse safety events including a patient death in a clinical trial cohort.
Adverse reaction monitoring and contraindications are critical parameters in pharmacological risk-benefit evaluation.
- FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) (U.S. Food and Drug Administration, 2023-09-29)
Key scientific uncertainties: Long-term continuous stimulation of somatotropes and sustained supra-physiological IGF-1 exposure.
Egypt Peptides enforces strict transparency regarding scientific limitations and gaps in longitudinal clinical data.
- FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) (U.S. Food and Drug Administration, 2023-09-29)
NOT ESTABLISHED. No approved human dose exists.
Under medical governance mandates, clinical study dosages represent strictly controlled experimental parameters and must never be interpreted as individual therapeutic advice.
- FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) (U.S. Food and Drug Administration, 2023-09-29)
Storage status: NOT ESTABLISHED. Unapproved for commercial human pharmacy distribution.
Peptide integrity degrades rapidly when exposed to elevated temperatures, repeated freeze-thaw cycles, or direct UV light exposure.
- FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) (U.S. Food and Drug Administration, 2023-09-29)
Yes. Unapproved pharmacological substances are strictly prohibited at all times in competitive sports under WADA Category S0 (Non-approved substances) or Category S2.
Athletes subject to drug testing face strict liability and multi-year competition bans upon detection of prohibited peptides or their metabolites.
- World Anti-Doping Agency (WADA) Prohibited List: Non-Approved Substances (S0) and Peptide Hormones (S2) (World Anti-Doping Agency, 2024-01-01)
- FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) (U.S. Food and Drug Administration, 2023-09-29)
Egypt Peptides provides peer-reviewed scientific reference monographs for research documentation. We strictly prohibit individual medical consultations, reconstitution guides, stacking recipes, or off-label use instructions.
All scientific claims must link to verified authoritative sources (FDA, PubMed, ClinicalTrials.gov) with zero tolerance for ungrounded marketing claims.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (The Journal of Clinical Endocrinology & Metabolism, 2006-03-01)
Authoritative Sources & Literature Registry
Regulatory dossiers, clinical trial registries, and peer-reviewed studiesWorld Anti-Doping Agency (WADA) Prohibited List: Non-Approved Substances (S0) and Peptide Hormones (S2) ↗
https://www.wada-ama.org/en/prohibited-list
FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) ↗
https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults ↗
https://doi.org/10.1210/jc.2005-1536